TY  - JOUR
AU  - Hussain, Maha
AU  - Mateo, Joaquin
AU  - Fizazi, Karim
AU  - Saad, Fred
AU  - Shore, Neal
AU  - Sandhu, Shahneen
AU  - Chi, Kim N
AU  - Sartor, Oliver
AU  - Agarwal, Neeraj
AU  - Olmos, David
AU  - Thiery-Vuillemin, Antoine
AU  - Twardowski, Przemyslaw
AU  - Roubaud, Guilhem
AU  - Özgüroğlu, Mustafa
AU  - Kang, Jinyu
AU  - Burgents, Joseph
AU  - Gresty, Christopher
AU  - Corcoran, Claire
AU  - Adelman, Carrie A
AU  - de Bono, Johann
AU  - PROfound Trial Investigators
PY  - 2020
DO  - 10.1056/NEJMoa2022485
UR  - http://hdl.handle.net/10668/16290
T2  - The New England journal of medicine
AB  - We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying...
LA  - en
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - Ataxia Telangiectasia Mutated Proteins
KW  - Bridged-Ring Compounds
KW  - Cyclin-Dependent Kinases
KW  - Genes, BRCA1
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Metastasis
KW  - Phthalazines
KW  - Piperazines
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Survival Analysis
KW  - Taxoids
TI  - Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
TY  - research article
VL  - 383
ER  -